Clinical Trial Update: TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial exploring transarterial chemoembolization (TACE) combined with sorafenib for unresectable hepatocellular carcinoma. The update highlights a potent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• DILANTIN (Phenytoin sodium, extended release)
• Nexavar (Sorafenib)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: PHENYTOIN/SORAFENIB [VA Drug Interaction], Carcinoma, Hepatocellular | Phase 2 | Status: UNKNOWN